Plumbing the core and nibbling at the margins of cancer

How to Decide to Offer a New Lab Test

Jared N. Schwartz, MD PhD LLC Past President, College of American Pathologists; Opinions his own; Charlotte, NC Q: Pathologists are faced with the need to set up additional lab tests routinely. Immunotherapy for cancer is the current rage. How does a pathologist decide whether and how to offer a new test such as PD-L1 Expression […]

Mutational Oncology: The Basics

Vivian B. Douglas, PhD. Associate Knowledge Engineer, CollabRx San Francisco, California Q: Many mature clinicians find “Mutational Oncology” to be a bit mysterious. Please help them understand. As they pertain to cancer, what are somatic (as opposed to germ line) mutations, transitions, transversions, “point”, “missense”, “nonsense”, insertion, deletion, and copy numbers and why does it […]

The Most Relied Upon Journals in Precision Oncology

Q: The medical world is running amuck with new info, some credible, some not. What are the most reliable sources of information in Precision Oncology?

Canadian/American Cancer

Cynthia Martin, MA is a freelance/ghost writer (who tried to write a serious piece). Q: As a journalist, you are a savvy native Canadian consumer/patient who also knows a lot about the United States. What do you see as the main similarities and differences between cancer prevention and care in the US and Canada? A: […]

Conflict of Interest in Cancer Clinical Trials

Kevin B. Knopf, MD MPH, Medical Director, Cancer Commons San Francisco, California Q: Clinical trials are the lifeblood of continuing drug development in the US. Yet they are often undersubscribed. What do you see as key conflicts of interest in recruiting for patients in the academic medical center, the hospital, and the private oncologists’ practice? […]